Comments
Strides Shasun today said it has received approval from the US health regulator for memantine hydrochloride tablets used in the treatment of dementia.
The product will be manufactured at the company’s facility at Bengaluru and marketed by Strides Pharma Inc in the US market.
In a BSE filing, Strides Shasun said it has received approval from the United States Food and Drug Administration (USFDA) for memantine hydrochloride tablets USP, 5mg and 10 mg.
“The product will be launched immediately,” it added.
Quoting IMS sales data, Strides Shasun said the US market for memantine hydrochloride tablets USP, 5mg and 10 mg is approximately USD 60 million.
Strides Shasun stock was trading 6.25 per cent lower at Rs 849.85 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.